Product Details
Iodoral is a high potency iodine/potassium iodide supplement. One
tablet of Iodoral supplies an amount of total elemental iodine,
comparable to the average daily intake of this essential element by
mainland Japanese, a population with a very low prevalence of
fibrocystic disease of the breast and breast cancer.
Iodine is an essential element. Although its main function is in
the production of thyroid hormones by the thyroid gland, other organs
in the body have a need for iodine in order to function normally (4).
Several studies have demonstrated a relationship between low
iodine intake and fibrocystic disease of the breast (FDB), both in
women and laboratory animals (1,2). The minimum amount of iodine
required for control and prevention of FDB is equivalent to 0.1mg/kg
body weight/day. For example, for a 50 kg woman, the daily amount of
iodine would be 5 mg.
The thyroid gland needs iodide to function properly. The original study
done 80 years ago to control goiter in adolescent girls used 9 mg
iodide daily (3). During the early 1900s, the iodine/iodide solution
called Lugol solution was used extensively, effectively and safely in
medical practice, for both low activity and above normal activity of
the thyroid gland (4). The recommended daily intake for iodine
supplementation was 2 to 6 drops of Lugol solution containing 12.5 to
37.5 mg total iodide.
That amount was mentioned as lately as 1995 in a book on Pharmaceutical
Sciences (5). Several investigators have shown convincing evidence
connecting inadequate iodine intake and breast cancer (6). Japanese
women living in Japan consumed a daily average of 13.8 mg total
elemental iodine and they experience one of the lowest prevalence
(risk) for breast, ovarian and uterine cancer (6).
In the 1960s, one slice of bread in the USA contained the full RDA of
0.15 mg iodine. The risk for breast cancer was then 1 in 20 (7). Over
the last 2 decades, iodine was replaced by bromine in the bread making
process. Bromine blocks thyroid function and may interfere with the
anticancer effect of iodine on the breast (4). Now, the risk for breast
cancer is 1 in 8 and increasing 1% per year (7).
The RDA limits for vitamins and minerals were established after
World War II. One of the last essential elements included in the RDA
system was iodine, established in 1980 and confirmed in 1989 (8). The
RDA for iodine was based on the amount of iodine/iodide needed to
prevent goiter, extreme stupidity and hypothyroidism (9).
The optimal requirement of the whole human body for iodine has never
been studied. Therefore, the optimal amount of this element for
physical and mental well-being is unknown. Based on demographic studies,
the mainland Japanese consumed an average of 13.8 mg daily and they are
one of the healthiest people on planet earth (6).
Lugol solution is a time-tested preparation with a proven track record
for over 150 years. Two drops contain 12.5 mg iodine/iodide, an amount
very close to the 13.8 mg average intake of mainland Japanese.
Administration of iodine/iodide in liquid solution is not very
accurate, may stain clothing, has an unpleasant taste and causes
gastric irritation. Iodoral is a precisely quantified tablet form
containing 5 mg iodine and 7.5 mg iodide as the potassium salt. To
prevent gastric irritation, the iodine/iodide preparation was absorbed
unto a colloidal silica excipient; and to eliminate the unpleasant
taste of iodine, the tablets were coated with a thin film of
pharmaceutical glaze (10).
Recommended Use:
Adults: Take 1 tablet per day or as directed by your physician.
Work closely with your physician while on the Iodoral program. Report
to your physician any history of thyroid surgery and/or radiation,
chronic lymphocytic thyroiditis (Hashimoto), and any previous problem
with your thyroid. Before starting Iodoral, your physician will order
blood tests for hematology, blood chemistry and thyroid functions. He
will also perform an ultrasound of your thyroid to measure the size and
appearance of your thyroid.
Depending on the results of the thyroid function tests and
ultrasound, he may order some blood tests for thyroid antibodies. If
you are taking thyroid hormones, let your physician know about it. Be
aware that Iodoral enhances the response of your body to thyroid
hormones (4,6).
Subjects on Iodoral feel warmer in cold environments and that is
expected. However, you will need to cut down the amount of thyroid
hormones if you experience palpitation, anxiety, increased sweating and
intolerance to heat. That is because Iodoral decreases your need for
thyroid hormones. Your physician will guide you in titrating downward
the amount of thyroid hormones. Your physician will reevaluate you one
month afterward if you are on thyroid hormones, and 3 months if not.
Keep a record of what you observe while on Iodoral and show it to your
physician.
To test whole body sufficiency for iodine, 4 tablets of Iodoral
are ingested, followed by 24 hr. urine collection. The more deficient a
subject is in iodine, the more iodine is retained by the body and the
least excreted in the urine. Sufficiency is achieved when 90% or more
of the ingested amount is excreted in the urine.
In most subjects tested, 3-4 tablets of Iodoral/day were required to
achieve whole body sufficiency within 3 months and the body retained
approximately 1.5 gm iodine at sufficiency (4,8). The best response in
patients with FDB was observed with ingestion of 2 tablets twice a day
(8). Check with your physician for more information about the loading
test.
Potential Side Effects: Ingestion of iodine and/or iodide has
been associated with certain complaints. If you experience any of the
following, stop ingesting Iodoral and contact your physician:
acne-like skin lesions in certain areas of your body
headache in the frontal sinus
unpleasant brassy taste
increased salivation and sneezing
If you experience any unusual symptom since starting on Iodoral, contact your physician.
References:
1) Ghent, W., et al, Can. J. Surg., 36:453-460,1993.
2) Eskin, B., et al, Biological Trace Element Research, 49:9-19, 1995.
3) Marine, D., Atl. Med. J., 26:437-442, 1923.
4) Abraham,G.E., The Original Internist, 11:17-36, 2004.
5) Gennaro A.R., Remington: 19th Edition, 1995, Mack Publishing Co, 1267.
6) Abraham, G.E., Flechas, J.D., Hakala, J.C., The Original Internist, 9:30-41, 2002.
7) Epstein, S.S., et al, Breast Cancer Prevention Program Macmillan, NY, 1998, pg5.
8) Abraham, G.E., The Original Internist, 11:(2) 29-38, 2004.
9) Abraham, G.E. Townsend Letter, 245:100-101, 2003.
10) Abraham, G.E., Flechas, J.D., Hakala, J.C., The Original Internist, 9:5-20, 2002.
|